» Articles » PMID: 1191567

Hereditary Giant Platelet Syndrome. Absence of Collagen-induced Coagulant Activity and Deficiency of Factor-XI Binding to Platelets

Overview
Journal Br J Haematol
Specialty Hematology
Date 1975 Apr 1
PMID 1191567
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The platelets from two related patients with the hereditary giant platelet syndrome were examined. They were larger than normal but otherwise ultrastructurally normal; they contained increased storage pools of adenine nucleotides and heparin-neutralizing activity and took up serotonin at an increased rate. They aggregated normally with ADP and collagen but failed to aggregate with bovine factor VIII and Ristocetin. Some change in shape occurred with ADP, and the reduction in adenylate energy change after addition of ADP to platelet-rich plasma was smaller than normal. Platelet coagulant activities including contact product forming activity, intrinsic factor-Xa forming activity and platelet factor 3 activity were normal or increased, but collagen-induced coagulant activity was absent whether tested in washed platelet suspensions or platelet-rich plasma. Platelet washing experiments showed decreased binding of factors V and VIII to hereditary giant platelets and no detectable factor XI in washed platelet suspensions. It is concluded that (1) the hereditary giant platelets studied lacked a binding mechanism for factors, V, VIII and XI; (2) the normal development of collagen-induced coagulant activity apparently depends upon the binding of factor XI to the platelet membrane; and (3) the defective prothrombin consumption observed in these patients may have resulted from the failure of their platelets to bind factor XI.

Citing Articles

The GPIbα intracellular tail - role in transducing VWF- and collagen/GPVI-mediated signaling.

Constantinescu-Bercu A, Wang Y, Woollard K, Mangin P, Vanhoorelbeke K, Crawley J Haematologica. 2021; 107(4):933-946.

PMID: 34134470 PMC: 8968903. DOI: 10.3324/haematol.2020.278242.


8-BuS-ATP derivatives as specific NTPDase1 inhibitors.

Lecka J, Gillerman I, Fausther M, Salem M, Munkonda M, Brosseau J Br J Pharmacol. 2013; 169(1):179-96.

PMID: 23425137 PMC: 3632248. DOI: 10.1111/bph.12135.


Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2).

White-Adams T, Berny M, Tucker E, Gertz J, Gailani D, Urbanus R Arterioscler Thromb Vasc Biol. 2009; 29(10):1602-7.

PMID: 19661487 PMC: 2756776. DOI: 10.1161/ATVBAHA.109.187393.


Analysis of the glycoprotein and protein composition of Bernard-Soulier platelets by single and two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis.

Nurden A, Dupuis D, Kunicki T, Caen J J Clin Invest. 1981; 67(5):1431-40.

PMID: 7229034 PMC: 370710. DOI: 10.1172/jci110172.


Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent.

De Marco L, Shapiro S J Clin Invest. 1981; 68(2):321-8.

PMID: 6790574 PMC: 370802. DOI: 10.1172/jci110259.